Importantly, it is known that sorafenib inhibits VEGF and several tyrosine kinase receptors involved in tumor cell proliferation and tumor angiogenesis, including platelet-derived growth factor receptor-b (PDGF), which are factors known to be overexpressed in neovascular AMD [24,25]. This evidence concerns the gene NTRK1 and neoplasm.